• Oct 5, 2026

  $1,143.12+0.02%

  Eli Lilly closed almost unchanged, up 0.02%, while comparable pharmaceutical companies fell 0.99% on average, with 4 of 6 lower [3]. The Motley Fool noted that Eli Lilly is partnering with Ginkgo Bioworks on drug discovery [2]. Seeking Alpha reported that Ginkgo Bioworks surged 21% on the day after the Eli Lilly TuneLab deal [1].

  • 1Seeking Alpha
  • 2The Motley Fool
  • 3Peer group

• Oct 2, 2026

  $1,142.85-0.61%

  Eli Lilly closed down 0.61%. Pr Newswire reported that the FDA approved an expanded indication for Jaypirca in certain patients with previously untreated CLL/SLL [1], and Seeking Alpha covered the same approval [2]. The items hold no sector or market figure and no stated cause for the decline, so the approval did not coincide with a gain.

  • 1Pr Newswire
  • 2Seeking Alpha

• Oct 1, 2026

  $1,149.85-0.62%

  Comparable pharmaceutical companies fell 1.77% on average, with all 6 of 6 declining [1]. Lilly's decline of 0.62% was smaller than the cohort's average and came alongside that group-wide weakness [1].

  • 1Peer group

• Sep 30, 2026

  $1,157.08-2.33%

  Eli Lilly fell 2.33% on a day when comparable pharmaceutical companies fell 1.32% on average, with all 6 of 6 lower [1]. Seeking Alpha reported a mid-stage Zepbound combination trial with superior weight loss [2] and a late-stage trial win for Ebglyss in hand-and-foot atopic dermatitis [3]. Volume was 1.5x its trailing average [4].

  • 1Peer group
  • 2Seeking Alpha
  • 3Seeking Alpha
  • 4Market data

• Sep 29, 2026

  $1,184.63-0.01%

  Seeking Alpha reported that Lilly said Zepbound at higher doses topped Novo's Wegovy HD [1]. It also reported that Novo said Ozempic 2 mg cut major cardiovascular events compared with Lilly's Mounjaro in a real-world claims analysis [2]. The shares closed essentially unchanged.

  • 1Seeking Alpha
  • 2Seeking Alpha

• Sep 28, 2026

  $1,184.78+0.11%

  Seeking Alpha reported, citing Bloomberg, that CEO David Ricks said Lilly was hunting for bigger deals in infectious disease, women's health and mental health, targeting earlier stage assets [1]. The shares closed little changed.

  • 1Seeking Alpha

• Sep 25, 2026

  $1,183.46+0.13%

  Eli Lilly shares closed little changed as the FDA expanded the approved use of Olumiant to cover severe alopecia areata in patients 12 and older [1]. The same day, a jury awarded Nektar $90 million plus interest in a trial involving Lilly [2].

  • 1Seeking Alpha
  • 2Seeking Alpha

Closing prices for LLY. Summaries describe past sessions only and are not advice, a forecast or a recommendation.

Headlines are published by third parties and linked as reported. Amaltash does not endorse or verify them.